Mimetic Medicines
Summary
Mimetic Medicines is developing a pipeline of novel, long-acting, non-opioid drug candidates for chronic pain. Mimetic’s drug candidates take advantage of the company’s proprietary short lipidated peptide (“SLiP”) platform to target ion channel / scaffold protein complexes that become dysregulated in patients with chronic pain.
Team
John Strumbos, PhD Co-Founder & CEO
As the CEO of Mimetic, Dr. Strumbos leverages not only his own operational leadership experience, but also his prior 15 years as a biopharmaceutical investor and advisor. At Weiss Multi-Strategy Advisors and Citadel Global Equities, he was responsible for stewarding capital to individual companies as well as managing risk for his portfolios. At Goldman Sachs and Morgan Stanley, he developed an intimate familiarity with hundreds of biotech companies across all therapeutic areas, development stages, and MOAs. Prior to co-founding Mimetic Medicines, he held executive leadership roles at Delin Ventures, Scipher Medicine, and Immunovant.
Dr. Strumbos earned his Ph.D. in Neuroscience from Yale University, M.B.A. from the Yale School of Management, and B.A. in Neuroscience from Columbia University. As an ion channel electrophysiologist by training, he finds it deeply fulfilling to lead development of a portfolio of novel drug candidates to help patients in need of safe, non-addictive pain relief.
Rasheen Powell, Ph.D. Co-founder & Chief Scientific Officer
After pioneering the therapeutic use of short lipidated peptides (SLiPs) while pursuing a doctorate at U. at Buffalo’s Jacobs School of Medicine & Biomedical Sciences, Dr. Powell completed his post-doctoral fellowship at Boston Children’s Hospital under the supervision of Clifford Woolf, M.B., B.Ch., Ph.D. He has published his research in peer-reviewed scientific journals such as Nature Communications, FASEB, Pain, and JCI. He is an inventor on multiple patents covering therapeutic interventions for pain.
Arin Bhattacharjee, PhD Co-Founder & Scientific Advisory Board Member
Dr. Bhattacharjee is an expert in pain research and neuronal ion channel trafficking. He is a tenured professor at the U. at Buffalo’s Jacobs School of Medicine & Biomedical Sciences. He has co-authored 38 peer-reviewed journal publications and is an inventor on 3 patents, all covering therapeutic interventions for pain. Dr. Bhattacharjee completed a post-doctoral fellowship at Yale University, earned a Ph.D.in Pharmacology from the University of South Alabama, and received a B.S. in Biology from the University of Alberta.
